The Wellcome Trust / Crucell N.V. / GlaxoSmithKline Biologicals / Emergent BioSolutions / Sanofi / TB / RESULTS UK Both / /
Country
Estonia / Cambodia / Mozambique / South Africa / Kenya / Uganda / United States / United Kingdom / /
Currency
GBP / USD / /
Event
FDA Phase / Business Partnership / /
Facility
Health’s National Institute of Allergy / University of Cape Town / Oxford University / Saint Louis University / Recombinant BCG Announced Building / Albert Einstein College of Medicine / Kenya Medical Research Institute / / /
IndustryTerm
value chain / /
MedicalCondition
HIV / disease / XDR / tuberculosis / /
Organization
National Institute of Health / UK Department for International Development / Cambodian Health Committee / Aeras Africa Office / University of Cape Town / US National Institutes of Health’s National Institute of Allergy and Infectious Diseases / Statens Serum Institut / Global Response Mission / US Food and Drug Administration / Albert Einstein College of Medicine / Kenya Medical Research Institute / FDA / Aeras Global TB Vaccine Foundation / Oxford University / Saint Louis University / US Centers for Disease Control and Prevention / /
Person
Peter Small / Robin Dean-Fourie / Louise Holly / John-Michael Maas / Richard Lord / / /
Position
Senior Program Officer / CEO / Deputy Director / President and CEO / /
Product
M72 / TB / AERAS-422 / Kenya / TB vaccine / Recombinant BCG Announced / /
AERAS Logo Tag CMYK ƒ reversed